Literature DB >> 12865322

Characterization of the androgen-regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter.

Wing-Shing Cheng1, Valeria Giandomenico, Ira Pastan, Magnus Essand.   

Abstract

TARP (T cell receptor gamma-chain alternate reading frame protein) is uniquely expressed in males in prostate epithelial cells and prostate cancer cells. Here we demonstrate that TARP expression is regulated by testosterone at the transcriptional level through specific binding of androgen receptor to an androgen response element in the proximal TARP promoter. We further demonstrate that the promoter specifically initiates reporter gene expression in TARP-positive prostate cancer cell lines. To develop a regulatory sequence for prostate-specific gene expression, we constructed a chimeric sequence consisting of the TARP promoter and the prostate-specific antigen (PSA) enhancer. We found that in the prostatic adenocarcinoma cell line LNCaP, the transcriptional activity of the regulatory sequence consisting of a TARP promoter and PSA enhancer is 20 times higher than the activity of a regulatory sequence consisting of the PSA promoter and PSA enhancer. Thus, our studies define a regulatory sequence that may be used to restrict expression of therapeutic genes to prostate cancer cells and may therefore play a role in prostate cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865322     DOI: 10.1210/en.2003-0121

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Authors:  Mark P Labrecque; Ilsa M Coleman; Lisha G Brown; Lawrence D True; Lori Kollath; Bryce Lakely; Holly M Nguyen; Yu C Yang; Rui M Gil da Costa; Arja Kaipainen; Roger Coleman; Celestia S Higano; Evan Y Yu; Heather H Cheng; Elahe A Mostaghel; Bruce Montgomery; Michael T Schweizer; Andrew C Hsieh; Daniel W Lin; Eva Corey; Peter S Nelson; Colm Morrissey
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

2.  Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.

Authors:  Sandra M Lopez; Alexander I Agoulnik; Manqi Zhang; Leif E Peterson; Egla Suarez; Gregory A Gandarillas; Anna Frolov; Rile Li; Kimal Rajapakshe; Christian Coarfa; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik
Journal:  Clin Cancer Res       Date:  2016-03-11       Impact factor: 12.531

3.  Molecular characterization of the feline T-cell receptor γ alternate reading frame protein (TARP) ortholog.

Authors:  Alexander Th A Weiss; Marie-Charlotte von Deetzen; Werner Hecht; Manfred Reinacher; Achim D Gruber
Journal:  J Vet Sci       Date:  2012-12       Impact factor: 1.672

4.  Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance.

Authors:  Guillermo C Rivera-Gonzalez; Alastair P Droop; Helen J Rippon; Katrin Tiemann; Davide Pellacani; Lindsay J Georgopoulos; Norman J Maitland
Journal:  Nucleic Acids Res       Date:  2012-02-22       Impact factor: 16.971

5.  Chronic IL-1 Exposed AR+ PCa Cell Lines Show Conserved Loss of IL-1 Sensitivity and Evolve Both Conserved and Unique Differential Gene Expression Profiles.

Authors:  Shayna E Thomas-Jardin; Mohammed S Kanchwala; Haley Dahl; Vivian Liu; Rohan Ahuja; Reshma Soundharrajan; Nicole Roos; Sydney Diep; Amrit Sandhu; Chao Xing; Nikki A Delk
Journal:  J Cell Signal       Date:  2021-12

6.  Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer.

Authors:  L Khandrika; R Lieberman; S Koul; B Kumar; P Maroni; R Chandhoke; R B Meacham; H K Koul
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

7.  Tumor-associated antigens for specific immunotherapy of prostate cancer.

Authors:  Andrea Kiessling; Rebekka Wehner; Susanne Füssel; Michael Bachmann; Manfred P Wirth; Marc Schmitz
Journal:  Cancers (Basel)       Date:  2012-02-22       Impact factor: 6.639

Review 8.  TARP as antigen in cancer immunotherapy.

Authors:  Jolien Vanhooren; Charlotte Derpoorter; Barbara Depreter; Larissa Deneweth; Jan Philippé; Barbara De Moerloose; Tim Lammens
Journal:  Cancer Immunol Immunother       Date:  2021-05-29       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.